Study #2020-0195
A Phase 1 Study of the Safety and Tolerability of COM902 in Subjects with Advanced Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
Dose escalation: COM902 monotherapy., Combination Product: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy., Cohort expansion: COM902 in combination with COM701 (both at the RDFE)., Combination Product: Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.
Description
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
Study phase:
Phase I
Physician name:
Ecaterina Ileana Dumbrava
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-760-2503
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.